A detailed history of Advisor Resource Council transactions in Abb Vie Inc. stock. As of the latest transaction made, Advisor Resource Council holds 5,640 shares of ABBV stock, worth $967,372. This represents 0.3% of its overall portfolio holdings.

Number of Shares
5,640
Previous 4,325 30.4%
Holding current value
$967,372
Previous $670,000 53.28%
% of portfolio
0.3%
Previous 0.06%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 19, 2024

BUY
$159.82 - $182.1 $210,163 - $239,461
1,315 Added 30.4%
5,640 $1.03 Million
Q4 2023

Jan 12, 2024

SELL
$137.6 - $154.97 $21,190 - $23,865
-154 Reduced 3.44%
4,325 $670,000
Q3 2023

Oct 24, 2023

SELL
$133.59 - $154.65 $16,030 - $18,558
-120 Reduced 2.61%
4,479 $667,000
Q2 2023

Jul 13, 2023

SELL
$132.51 - $164.9 $195,319 - $243,062
-1,474 Reduced 24.27%
4,599 $619,000
Q1 2023

Apr 25, 2023

BUY
$144.61 - $166.54 $83,873 - $96,593
580 Added 10.56%
6,073 $967,000
Q4 2022

Jan 20, 2023

SELL
$138.31 - $165.87 $73,995 - $88,740
-535 Reduced 8.88%
5,493 $0
Q3 2022

Oct 26, 2022

SELL
$134.21 - $153.93 $880,014 - $1.01 Million
-6,557 Reduced 52.1%
6,028 $809,000
Q2 2022

Jul 27, 2022

SELL
$137.62 - $174.96 $41,561 - $52,837
-302 Reduced 2.34%
12,585 $1.93 Million
Q1 2022

Apr 20, 2022

SELL
$131.98 - $163.75 $951,179 - $1.18 Million
-7,207 Reduced 35.87%
12,887 $2.09 Million
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $593,335 - $750,741
5,523 Added 37.9%
20,094 $2.72 Million
Q3 2021

Nov 16, 2021

SELL
$106.4 - $120.78 $343,459 - $389,877
-3,228 Reduced 18.14%
14,571 $1.57 Million
Q2 2021

Aug 19, 2021

BUY
$105.21 - $117.21 $1.66 Million - $1.85 Million
15,794 Added 787.73%
17,799 $2.01 Million
Q2 2021

Aug 13, 2021

BUY
$105.21 - $117.21 $210,946 - $235,006
2,005 New
2,005 $225,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $303B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Advisor Resource Council Portfolio

Follow Advisor Resource Council and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Resource Council, based on Form 13F filings with the SEC.

News

Stay updated on Advisor Resource Council with notifications on news.